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Purpose: Taste and smell alterations (TSAs) are common symptoms in patients with cancer that may
interfere with nutritional intake and quality of life. In this study, we explore and describe how charac-
teristics of self-reported TSAs change in individuals with lung cancer over time using a multiple case
study approach to present longitudinal data from individuals.
Methods: Patients under investigation for lung cancer were recruited from one university hospital in
Sweden. The 52 patients providing data eligible for the analyses presented here were those treated for
primary lung cancer with three measurement time-points, of which one was prior to treatment and two
after treatment start. Four self-report instruments were used for data collection. These included the Taste
and Smell Survey, used to characterize TSAs for each individual at the three time-points and instruments
measuring nutritional status, symptom burden and well-being. Three patient cases are described in
detail to illustrate variation in individual experiences of TSAs.
Results: The characteristics of the TSAs experienced changed over time for many of the individuals in this
study, including those undergoing surgery or stereotactic radiotherapy. The case descriptions show how
the individual experiences of TSAs and the impact on daily life of these symptoms not only depend on
TSA characteristics, but may be inﬂuenced by contextual factors, e.g. other symptoms and life situation.
Conclusions: Our results suggest that healthcare professionals need to consider the variation in char-
acteristics of TSAs among and within patients over time, and be attentive to individual experiences of
TSAs.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
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Ltd. This is an open access article usymptoms in patients with cancer that may interfere with nutri-
tional intake and quality of life (Hutton et al., 2007; Zabernigg et al.,
2010). Although TSAs have most often been studied in relation to
cancer treatments such as chemotherapy and radiotherapy to the
head-neck area, they have also been reported at the time of diag-
nosis and in palliative phases of cancer (Belqaid et al., 2014;
Gamper, Zabernigg et al., 2012; Hutton et al., 2007; Yamashita
et al., 2006).
One research strategy to assess taste function is to clinically
test recognition and detection thresholds of the basic taste qual-
ities (sweet, sour, salt, bitter and umami) or odours (Wismer,
2008). However, in the Swedish study presented here we were
interested in patients' experiences of TSAs rather than their taste
and smell acuity and we therefore used a self-report instrument tonder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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research has acknowledged the lack of consensus surrounding the
concepts and words used for describing altered taste and smell
experiences during cancer (Boltong and Keast, 2015). For instance,
‘taste’ is often confused with ﬂavour making it difﬁcult to differ-
entiate these concepts. Furthermore, ﬂavour is a term which does
not exist in the Swedish language. Based on that and in line with
previous research (Bernhardson et al., 2008a; Steinbach et al.,
2009; Gamper, Zabernigg et al., 2012) we have used the words
“taste” and “taste and smell” in their colloquial sense to encom-
pass ﬂavour, taste and/or smell. When we refer to the sense of
taste in terms of the basic taste qualities, we use the term “basic
taste”.
Prior longitudinal studies of TSAs have shown that, at group
level, mean intensity scores of self-reported taste changes
measured on a 4-point Likert scale, increase during the patient's
course of chemotherapy (Gamper, Giesinger et al., 2012;
Zabernigg et al., 2010). Steinbach et al. (2009) provided comple-
mentary information by clinically testing senses of taste and
smell, and found, also at group level, increasingly impaired basic
taste and smell function during chemotherapy. Similar results
were presented by Boltong et al. (2014), who found an overall
reduced taste function in patients undergoing chemotherapy and
a cyclical change associated with proximity to chemotherapy
administration; however they also reported taste function being
restored eight weeks after completed chemotherapy. In a quali-
tative study by Bernhardson et al. (2007), patients undergoing
chemotherapy were interviewed about their TSAs. They found
that problems with taste and smell improved gradually after
completed treatment, ceasing completely after 0.5e14 weeks.
Brisbois et al. (2011) addressed differences in qualities of TSAs by
grouping patients according to self-reported increased or
decreased sensitivity to basic taste qualities (sweet, salt, sour and
bitter) or smell. Our recent research developed this further to also
account for self-reported TSAs that do not involve intensity
changes, such as metallic taste or reduced enjoyment of speciﬁc
foods (McGreevy et al., 2014). In that cross-sectional study, we
observed gender differences among the groups describing
different TSA qualities.
Although studies of groups of patients present important
information about TSAs in patients with cancer, they do not
reveal the nature of the individual experiences underlying group
averages. Systematic study of individual experiences of TSAs
may thus provide information of particular relevance for
healthcare professionals dealing with symptomatic individuals
in their daily practice. In addition, while the previously
mentioned longitudinal studies using symptom intensity scoring
provide descriptive information about some central aspects of
TSAs, they do not give insight into other types of changes in
taste and smell. Few studies to date have investigated the many
different qualities of perceived TSAs, such as increased or
decreased sensitivity in basic taste qualities or smell, and lon-
gitudinal data on this is particularly lacking. It is also important
to consider that many of the different qualities of TSAs are not
mutually exclusive, as an individual patient can experience
several changes simultaneously.
This complexity led us to recognize that our previous results
(Belqaid et al., 2014; McGreevy et al., 2014) did not adequately
represent patients' individual experiences of TSAs. In the study
presented here, we address these knowledge gaps by exploring and
describing howcharacteristics of TSAs change in individuals treated
for lung cancer over time. For this purpose, we have chosen a
multiple case study design (Yin, 2014), allowing the combination of
complementary data types to further understanding of individuals'
experiences of TSAs.2. Methods
The data presented here derive from the longitudinal “Taste and
Smell project” which was approved by the Regional Ethical Review
Board, Stockholm (2009/1463-31/3; 2010/1849-32; 2011/1324-32).
2.1. Patients and data collection procedure
Patients under investigation for lung cancer were recruited
consecutively between January 2011 and July 2012 from one
university hospital in Stockholm, Sweden. Patients were informed
about the study by a staff nurse during their ﬁrst visit at the
outpatient clinic. If patients expressed interest in study partici-
pation, their contact information was forwarded to the researchers
who contacted them by telephone. After a patient had agreed to
participate and provided informed consent, one of four in-
terviewers (either a nurse or dietitian) carried out structured face-
to-face interviews based on the four questionnaires described
below. Patients were ﬁrst interviewed before treatment start, with
three follow-up interviews conducted thereafter at two-month
intervals. When feasible, the same interviewer conducted all in-
terviews, reading the questions aloud and documenting the pa-
tient's responses. After each interview, the research interviewer
compiled ﬁeld notes with information about the context of the
interview and other details of importance beyond that docu-
mented in the questionnaires. Additional clinical and background
information was obtained from medical records with patients'
consent.
Data for the analyses presented herewere derived from patients
participating in the “Taste and Smell project” who were treated for
primary lung cancer, and had documented interviews conducted at
a minimum of three of the four measurement time-points. Patients'
treatment modalities were dichotomized as those receiving 1)
systemic therapy, i.e. targeted therapy or chemotherapy, including
concomitant chemo-radiotherapy, and adjuvant chemotherapy af-
ter surgery; or 2) localized therapy, i.e. surgery or stereotactic
radiotherapy (SRT). Treatment start was registered as the ﬁrst day
of the targeted therapy or ﬁrst chemotherapy cycle, day of surgery
or ﬁrst day of SRT.
In this study, the ﬁrst measurement time-point, here referred to
as M1, was held before treatment start. The second measurement
time-point (M2) took place within 30e99 days after treatment
start, so that patients on chemotherapy should have received at
least two of their planned treatment cycles. The third measurement
time-point (M3) took place 100 days after treatment start, to
avoid overlap between time frames for M2 and M3. The exact
number of days between measurement time-point and the previ-
ous treatment for individual patients is not presented here as the
purpose of this study is to explore and describe changes in char-
acteristics of TSAs rather than establish patterns of effects of cancer
treatment on TSAs.
2.2. Questionnaires
The four self-report instruments used for data collection were
presented in the same order to all patients.
The ﬁrst instrument was the Swedish version of The Taste and
Smell Survey (TSS) (Heald et al., 1998; McGreevy et al., 2013). The
TSS is a 16-item TSA symptom-speciﬁc questionnaire, originally
developed for patients with HIV, but used in research settings with
patients with cancer in both Canada (Bernhardson et al., 2012;
Brisbois et al., 2011; Hutton et al., 2007) and Sweden (Belqaid
et al., 2014; McGreevy et al., 2013). The TSS consists both of items
with ﬁxed response alternatives and open-ended items to explore
perceived changes in taste and smell sequentially.
Fig. 1. Overview of the selection process. M, male; F, female. *Other reasons, e.g. major
co-morbidities, cognitive impairments, withdrawn consent.
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Assessment System (ESAS) (Bruera et al., 1991), which uses visual
analogue scales to assess nine symptoms: pain, tiredness, nausea,
depression, anxiety, drowsiness, loss of appetite, shortness of
breath and “other”. An additional item assesses general well-being.
Higher scores indicate greater symptom intensity.
The third instrument, the Functional Assessment of Anorexia-
Cachexia Therapy (FAACT), assesses aspects of well-being
(Ribaudo et al., 2000). Patients rate their level of agreement with
each of 40 statements on a ﬁve-point Likert scale. The statements
are grouped into ﬁve domains of which four concern physical, so-
cial, emotional and functional well-being, and the ﬁfth assesses
other eating-related problems.
The short form of the Scored Patient-Generated Subjective
Global Assessment (PG-SGA SF) (Bauer et al., 2002; Ottery, 1996;
Persson et al., 1999; Vigano et al., 2014) was the ﬁnal instrument
used to assess weight change, food intake at present compared to
“normal”, symptoms that may have interfered with food intake,
and perceived physical function.
2.3. Analysis and presentation of data
Traditional scoring of the TSS results in a “chemosensory
complaint score” of 0e16 (Heald et al., 1998), with items reﬂecting
TSAs' perceived nature and severity. In the study presented here,
we seek to disentangle these different aspects of TSAs.We therefore
adapted the use of TSS items and score to reﬂect TSA characteristics.
We used seven items from the TSS addressing qualities of TSAs to
categorise characteristics: ﬁve items assessing general changes in
perceptions of taste or smell including persistent bad taste in
mouth, and two items concerning changes in perception of in-
tensity in four basic taste qualities (sweet, salt, sour and bitter) and/
or smell.
Using the responses to these items, patients' TSAs were cat-
egorised into ﬁve TSA intensity categories according to their re-
ported change in perceived intensity of TSAs qualities as follows: 1)
no TSAs, 2) TSAswith stronger intensity of any or all of the basic taste
qualities and/or smell, 3) TSAs with weaker intensity of any or all of
the basic taste qualities and/or smell, 4) TSAs withmixed changes in
intensity including both stronger and weaker intensity of different
basic taste qualities and/or smell, and 5) other TSAs, including those
reporting general changes in perception of taste or smell, but
without speciﬁcation of intensity changes in basic taste qualities or
smell.
An additional strategy used here to present the data on char-
acteristics of TSAs is calculation of a summed score from the seven
TSS items described above. This score reﬂects the number of
different qualities of TSAs reported by one patient at a speciﬁc time-
point, giving an indication of what we here call the multiplicity of
TSAs. The TSA multiplicity score was calculated using the standard
TSS scoring, in which six items each yield either zero or one point,
and one item has four sub-items and therefore yields between
0 and 4 points, giving a total TSA multiplicity score ranging be-
tween 0 and 10.
We present the case study data in two different forms. First,
changes in TSA characteristics between different time-points are
cumulatively explored based on each individual; this is done by
graphically charting both the TSA intensity category and the TSA
multiplicity score for individual patients at each time point (M1, M2
andM3). These data are presented by treatment type and gender to
allow visual overview of changes over time which might facilitate
hypothesis generation. For example, systemic and localized treat-
ment might be postulated to affect TSAs through different mech-
anisms, and results from our previous research (McGreevy et al.,
2014) have suggested differences in TSA qualities between menand women.
We thereafter present narrative descriptions of three individual
cases to provide richer information about different experiences of
having TSAs in the context of a lung cancer disease and its treat-
ment. The case descriptions were summarized using data from the
interviewer's ﬁeld notes, responses to open-ended questions, and
answers to, or ratings of, selected items in the four questionnaires.
The names used here are ﬁctitious.
For demographic purposes, patients' smoking status was cat-
egorised as smoker, former smoker (quit >1 year ago) and non-
Table 1
Patient demographics and clinical characteristics.
Total N ¼ 52
Age (years) Mean; SD 66.8; 8.7
Gender, N (%) Men 21 (40)
Women 31 (60)
Education, N (%) Elementary school 13 (25)
High school 22 (42)
University 15 (29)
Other 2 (4)
Smoking status, N (%) Smoker 18 (35)
Former smoker 28 (54)
Non-smoker 6 (11)
Tumour type, N (%) NSCLC 44 (85)
SCLC 1 (2)
Other 7 (13)
Disease stage, N (%) I-IIIA 24 (46)
IIIB-IV 28 (54)
Treatment, N (%) Systemic 34 (65)
Localized 18 (35)
Days between M1 and treatment start Median 30.5
Min; max 1; 77
Days between treatment start and M2 Median 55.5
Min; max 30; 97
Days between treatment start and M3 Median 132
Min; max 100; 172
Days between M2 and M3 Median 65.5
Min; max 41; 137
NSCLC, non-small cell lung cancer; SCLC, small-cell lung cancer; Other includes unveriﬁed tumours, multiple tumours of different kinds, carcinoids and mesothelioma.
M1, measurement time-point before treatment start; M2, ﬁrst measurement time-point after treatment start; M3, second measurement time-point after treatment start.
Systemic treatment includes targeted therapy, chemotherapy, chemotherapy following surgery and combined chemoradiotherapy.
Localized treatment includes surgery and stereotactic radiotherapy.
Fig. 2. a and b. Individual changes over time in characteristics of TSAs in men treated with localized therapy (n ¼ 7), regarding a) TSA intensity categories and b) TSA multiplicity
scores (0e10). TSAs, taste and smell alterations M1, measurement time-point before treatment start; M2, ﬁrst measurement time-point after treatment start; M3, second mea-
surement time-point after treatment start. No TSAs: Patients not reporting any TSAs; Stronger: Patients reporting stronger intensity in any or all of the basic taste qualities or smell;
Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger and
weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no speciﬁcation in intensity changes in basic taste qualities or smell.
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made by the Swedish National Lung Cancer Registry (Swedish Lung
Cancer Registry Board, 2010).
3. Results
Of the 255 patients interviewed for the Taste and Smell Project,
52 patients met inclusion criteria with data at three time-points
eligible for analysis. See Fig. 1 for an overview of the selection
process. Patients' demographic and clinical characteristics are
shown in Table 1.3.1. Individual changes in characteristics over time
Figs. 2ae5a graphically represent individual changes in TSA
intensity categories over time according to gender and treat-
ment type. Only 14 of the 52 individuals included in the study
remained in the same TSA intensity category at all three time-
points, with 11 of these patients reporting no TSAs at each
time-point. Eighteen individuals shifted TSA intensity category
(no TSAs, stronger intensity, weaker intensity, mixed changes in
intensity or other TSAs) both between M1eM2 and between
M2eM3. Figs. 2be5b present the corresponding individual
Fig. 3. a and b. Individual changes over time in characteristics of TSAs in women with localized therapy (n ¼ 11), regarding a) TSA intensity categories and b) TSA multiplicity
scores (0e10). TSAs, taste and smell alterations M1, measurement time-point before treatment start; M2, ﬁrst measurement time-point after treatment start; M3, second
measurement time-point after treatment start No TSAs: Patients not reporting any TSAs; Stronger: Patients reporting stronger intensity in any or all of the basic taste qualities
or smell; Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger
and weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no speciﬁcation in intensity changes in basic taste qualities or smell.
-——— represents Beata, see case description in Box 1.
Fig. 4. a and b. Individual changes over time in characteristics of TSAs in men with systemic therapy (n ¼ 14), regarding a) TSA intensity categories and b) TSA multiplicity
scores (0e10). TSAs, taste and smell alterations M1, measurement time-point before treatment start; M2, ﬁrst measurement time-point after treatment start; M3, second
measurement time-point after treatment start No TSAs: Patients not reporting any TSAs; Stronger: Patients reporting stronger intensity in any or all of the basic taste qualities or
smell; Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger
and weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no speciﬁcation in intensity changes in basic taste qualities or smell.
-——— represents Carl, see case description in Box 2.
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multiplicity scores were relatively low among those who re-
ported experiencing any TSAs. Twenty-eight of the 52 in-
dividuals in the study had TSA multiplicity scores of 0e2 at all
time-points; it was only at the time-points after start of treat-
ment (M2, M3) that seven individuals reported TSA multiplicity
scores as high as 7e10. This also indicates that many of the in-
dividuals in this study reported an increase in TSA multiplicity
scores after treatment start, that is between M1eM2. This was
expected for the patients undergoing systemic treatment, but
Figs. 2b and 3b suggest that several of the men and women
treated with localized therapy also report increases in TSA
multiplicity scores between M1 and M2. However, many of these
individuals also report decreases in TSA multiplicity scores be-
tween M2 and M3.3.2. Narrative case descriptions
The cases of Beata, Carl and Gunilla are described in depth in
Boxes 1, 2 and 3, respectively; their reported TSA trajectories are
also indicated in Figs. 3a,b (Beata), 4ae4b (Carl), and 5ae5b
(Gunilla) with bold, broken lines.
Beata's case illustrates that patients may experience TSAs prior
to treatment. She is one of the individuals in our study who un-
derwent localized treatment and reported TSAs afterwards. Carl
was chosen to exemplify those persons who experienced TSAs
without intensity changes in basic taste qualities and smell during
chemotherapy treatment. Gunilla represents a typical scenario with
subtle TSAs before treatment start, but problems from alterations in
both taste and smell during concomitant chemo-radiotherapy.
These three case descriptions demonstrate that the consequences
Fig. 5. a and b. Individual changes over time in characteristics of TSAs in women with systemic therapy (n ¼ 20), regarding a) TSA intensity categories and b) TSA multiplicity
scores (0e10). TSAs, taste and smell alterations M1, measurement time-point before treatment start; M2, ﬁrst measurement time-point after treatment start; M3, second
measurement time-point after treatment start No TSAs: Patients not reporting any TSAs; Stronger: Patients reporting stronger intensity in any or all of the basic taste qualities
or smell; Weaker: patients reporting weaker intensity in any or all of the basic taste qualities or smell; Mixed: patients reporting mixed changes in intensity including both stronger
and weaker intensity of different basic taste qualities or smell; Other TSAs: patients reporting TSAs but with no speciﬁcation in intensity changes in basic taste qualities or smell.
-——— represents Gunilla, see case description in Box 3.
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characteristics of TSAs, but on an individual person and his/her
general life-situation as well as other symptoms and treatment
side-effects.
4. Discussion
Through this multiple case study approach, we are able to
expand further on our previous ﬁndings about the diversity of
characteristics of TSAs between individuals treated for primary
lung cancer (McGreevy et al., 2014) to also show that character-
istics of TSAs change over time within many individuals in our
study. However, our results also suggest that the individual ex-
periences of TSAs and the impact of these symptoms on daily life
may be inﬂuenced by individual and contextual factors such as
other symptoms, treatment side-effects and general life-
situation.
Previous longitudinal research has also demonstrated changes
in TSAs over time in relation to treatment, but studies have pri-
marily addressed TSAs in terms of self-reported symptom intensity
or as changes in thresholds of basic taste and smell function at
group level (Boltong et al., 2014; Gamper, Giesinger et al., 2012;
Steinbach et al., 2009; Zabernigg et al., 2010). Our results suggest
that not only intensity but also the characteristics of TSAs may
change over time in individuals in relation to treatment. This is
important information for health-care professionals, as the char-
acteristics of TSAs should be taken into consideration when
providing guidance and advice to patients for managing TSAs. For
example, a patient experiencing a general decrease in taste function
would not beneﬁt from the same recommendations as someone
who is bothered by a persistent bad taste in the mouth. Few
research studies to date have addressed management strategies for
TSAs (Thorne et al., 2015); our results suggest that follow-up of
patients experiencing TSAs is of critical importance in order to
adjust strategies to manage TSAs according to their changing
characteristics.
Based on previous research on TSAs in patients with cancer
(Bernhardson et al., 2008a; Joussain et al., 2013) we anticipated
that TSAs would present after start of systemic treatment. Inter-
estingly, several of the individuals in our study undergoing
localized treatment with surgery or SRT also reported perceivingTSAs after this treatment (at M2 and M3). There are research
reports of patients experiencing TSAs after surgery in the head-
neck and gastric area (Heiser et al., 2010; Wikman et al., 2014)
and a number of case reports of patients experiencing TSAs after
general anesthesia (Dhanani and Jiang, 2012; Konstantinidis et al.,
2009). The authors of these studies present theories for under-
lying mechanisms, which are often neurological, but also include
factors such as wound healing, postoperative changes in nutri-
tional intake, and side-effects of medications, all of which may be
applicable to the patients included in our study. To the best of our
knowledge, no previous study has reported changes in taste or
smell following surgery for lung cancer, which might thus be a
relevant topic for further investigation. Our results also show that
TSAs present not only following treatment, as focused on in
previous research, but also prior to treatment. This has been
investigated in more detail in our previous work (Belqaid et al.,
2014).
The narrative descriptions found in the three individual cases
of Beata, Gunilla and Carl also suggest that although the charac-
teristics of TSAs and changes in these, presented in Figs. 2e5a and
2e5b, reveal some aspects of the patient's individual experiences
of TSAs, they do not capture the whole picture. The case reports
illustrate different qualities of TSAs and the consequences of TSAs
on daily life, such as impaired food enjoyment, restricted social
life, and how the experience of TSAs are inﬂuenced by other
symptoms and side-effects from treatment. These results are in
line with previous research investigating the nature of TSAs and
their impact on daily life (Bernhardson et al., 2008b; Boltong et al.,
2012).
The case descriptions also provide additional information
about the individual experience of TSAs in relation to food intake:
Gunilla and Beata report similar characteristics of TSAs at the ﬁrst
follow-up after treatment start (M2), with both of them having
TSAs with mixed changes in intensity and rather high TSA mul-
tiplicity scores of eight and seven, respectively. However their
ratings on the PG-SGA SF checklist of symptoms interfering with
food intake differ. Whereas Gunilla reports that TSAs along with
other symptoms have affected food intake after treatment start,
Beata, who also reports eating problems, instead indicates
symptoms other than TSAs on this checklist. In our previous study
we found that although 38% of the 117 patients prior to treatment
Box 1
Case description, Beata.
K. Belqaid et al. / European Journal of Oncology Nursing 21 (2016) 232e241238for lung cancer reported TSAs on the TSS, as few as eight of these
indicated on the PG-SGA SF checklist that “taste changes” or
“being bothered by smells” had interfered with food intake
(Belqaid et al., 2014). When “taste changes” or “being bothered by
smells” were indicated on the PG-SGA SF symptoms checklist, itwas in conjunction with loss of appetite and/or nausea, which are
symptoms well known to impair food intake. This suggests that
other symptoms such as loss of appetite and nausea may be more
powerful drivers of reducing food intake, but that TSAs may
contribute and worsen the situation when presenting with these
Box 2
Case description, Carl.
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The interaction between TSAs and other concurring symptoms
should also include mention of the hedonic aspect of foods, which
can be difﬁcult to distinguish from the purely sensory perception of
basic taste and smell. Hedonics is a concept which refers to the
pleasantness and unpleasantness of sensory experience, for
example from the taste of foods (Boltong and Keast, 2012). For
instance, although different individuals may have the same sensory
experience of the taste of coffee, some people enjoy it whilst others
may not. The hedonic experience of foods has also been reported to
encompass hunger and appetite (Boltong and Keast, 2012), which
adds to the complexity of food enjoyment when experiencing
multiple symptoms. The case description of Carl exempliﬁes this, as
he says that it is not really his basic taste function that has changed,
but his liking of familiar foods.
The concepts used here of TSA intensity categories and TSA
multiplicity score have several limitations that should be consid-
ered. The TSA intensity categories indicate the type and direction of
a patient's perceived TSAs and allowed us to show how character-
istics of TSAs may change over time in individual patients inrelation to treatment start. However, the TSA intensity categories
do not contain information about the magnitude of the changes or
how bothersome they are perceived to be. Also note that for con-
sistency in categorization of TSA data, we used a strategy where we
prioritized reports of changes in perceived intensity of the basic
taste qualities or smell, such that only when no such changes were
reported did we use the category “other TSAs” for other reported
changes. The use of the TSA intensity categories is probably not
appropriate in clinical practice, as successful management of TSAs
demands more detailed information about an individual patient's
TSAs. The TSA multiplicity score reﬂects the number of different
TSAs reported by one patient and allowed us to show that many
individuals in our study reported a larger number of TSAs after start
of treatment. Limitations here include the TSS items used not being
mutually exclusive, as some are open-ended while others have
ﬁxed answer alternatives. Therefore, a patient could report the
same type of change in more than one item.
In this study, we chose a multiple case study approach to focus
on individuals. We do not claim that these individuals are neces-
sarily representative of the general lung cancer population; instead
Box 3
Case description, Gunilla.
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aware of the variation of the individual symptom experience. This
concerns both clinical practice and research, where individual
changes may be concealed in results reported at group level. We
argue that the case study approach is of particular interest for
health-care professionals, as they deal with the individual experi-
ences of disease and symptoms in their daily practice.
5. Conclusion
The results from this study further our understanding of
cancer-related TSAs by illustrating that the characteristics of TSAs
changed relative to the start of both systemic and localized
therapy. Furthermore, the complexity of the individual experi-
ences of TSAs suggest that health-care professionals should be
attentive to changes in characteristics of TSAs to adapt advice and
support to the individual needs and experiences of patients with
TSAs.
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